Rare Disease

From Boom to Regulatory Bust? The Evolving Landscape for Rare Genetic Disease Therapies

Explore the volatile world of rare disease biotechs in 2025, from Novartis's $12B Avidity acquisition sparking optimism to FDA scrutiny causing stock plunges for uniQure and Sarepta.

Solid Bioscience

The $12B Alarm Bell: Smart Money is Buying Solid Biosciences ($SLDB) While Retail Investors are Sleeping

Novartis's $12B acquisition of Avidity just repriced the gene therapy market, yet Solid Biosciences lags far behind. Top institutional investors see de-risked biology and standout safety in SLDB's early data. Are retail investors missing one of the most asymmetric opportunity in biotech?